Search Results
Your search for Blood matches 4668 pages
Showing 751 - 800Eytan Stein, MD, Appointed Chief of the Leukemia Service at MSK
Eytan M. Stein, MD, will assume the role of Chief of the Leukemia Service in the Division of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center (MSK), New York. Dr. Stein joined MSK as a medical oncology/hematology fellow in 2010, became a faculty member in 2013, and was appointed...
The Evolving Role of PI3K Inhibitors in Double-Refractory CLL
The treatment paradigm for chronic lymphocytic leukemia (CLL) continues to evolve in the first-line setting and beyond, with the availability of Bruton’s tyrosine kinase (BTK) inhibitors, the BCL2 inhibitor venetoclax, and novel combinations of these agents with anti-CD20 monoclonal antibodies....
With Newer Therapies, AML Diagnosis and Prognosis Evolve
For many years, treatment options for acute myeloid leukemia (AML) were limited mainly to the 7 + 3 regimen. However, more recently, a mini-explosion of AML therapies aimed at newly identified genetic targets makes discussions about treatment of this disease much more complicated. In fact, these...
High-Dose Chemotherapy and Stem Cell Transplant vs CAR T-Cell Therapy for Resistant DLBCL
Which is the preferred second-line treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL): high-dose chemotherapy and autologous stem cell transplantation (ASCT) or chimeric antigen receptor (CAR) T-cell therapy? This was the subject of a debate at the...
Newly Diagnosed AML: Induction to Maintenance
When it is dark enough, you can see the stars.” —Ralph Waldo Emerson Low-intensity therapy for older or unfit patients with acute myeloid leukemia (AML) was introduced in the early 2000s in the form of low-dose cytarabine or hypomethylation therapy (azacitidine or decitabine). Recent studies...
‘TRANSFORMING’ Our Thinking About Second-Line Therapy for High-Risk Large B-Cell Lymphoma: Bring in the CARs
As reported in The Lancet by Kamdar et al,1 and summarized in this issue of The ASCO Post, the international phase III TRANSFORM trial was completed in 184 patients with primary refractory or early (≤ 12 months) relapsed large B-cell lymphoma (LBCL). Patients were randomly assigned to receive...
Association of FLT3-ITD Measurable Residual Disease With Outcomes in Newly Diagnosed AML
In a study reported in the Journal of Clinical Oncology, Grob et al found that next-generation sequencing detection of FLT3-internal tandem duplication (FLT3-ITD) measurable residual disease (MRD) in complete remission was associated with markedly increased risk of relapse and poorer overall...
Phase I Trial Shows Experimental Mini-Protein May Be Able to Inhibit the Cancer-Driving MYC Gene
Researchers have found that a new drug may be able to target—and for the first time, inhibit—the function of the MYC gene. Until now, no other drug has been able to do this safely and effectively, according to findings from a phase I clinical trial published by Garralda et al in the European...
Preliminary Results From ARROS-1 Phase I Clinical Trial Suggest That NVL-520 May Be Well Tolerated and Active in NSCLC
Preliminary data from a phase I clinical trial of the ROS1 inhibitor NVL-520 to treat patients with non–small cell lung cancer (NSCLC) and other solid tumors suggested that it may have the potential to both halt tumor growth by inhibiting a cancer-causing gene change and reach cancer cells within...
Mosaic Chromosomal Alterations and Risk of Lung Cancer
In a study reported in The Lancet Oncology, Qin et al found that the presence of mosaic chromosomal alterations detected in blood-derived DNA was associated with an increased risk of lung cancer among persons of Chinese and European heritage. Study Details The study involved two cohorts:...
Cell-Free DNA Profiling in Patients With Advanced Cancers May Lead to Early Detection of Myeloid Malignancies
Researchers have found that an incidental finding of clonal hematopoiesis in liquid biopsies can be used to trigger hematologic tests to assess the risk of developing myeloid malignancies, according to a new study published by Tagliamento et al in the European Journal of Cancer. The findings were...
FDA Approves Oral MEK Inhibitor Cobimetinib for Histiocytic Neoplasms
The U.S. Food and Drug Administration (FDA) has approved cobimetinib (Cotellic), an oral inhibitor of MEK1 and MEK2, for the treatment of adult patients with the family of blood diseases known as histiocytic neoplasms. These diseases include Erdheim-Chester disease, Rosai-Dorfman disease, and...
The NordICC Trial: The Devil Is in the Details
Colorectal cancer ranks third among cancer deaths in both men and women in the United States, with an estimated 106,000 new cases and 52,000 deaths anticipated in 2022.1 Colorectal cancer rates have declined by approximately 2% per year from 2014 to 2018 in people over the age of 50 years, which is ...
Genomic Microsatellite Signature Assay to Identify Germline MMRD in Patients With CMMRD
In an analysis reported in the Journal of Clinical Oncology, Chung et al described the performance of a newly developed assay using genomic microsatellite signatures (LOGIC; low-pass genomic instability characterization) in detecting germline mismatch repair deficiency (MMRD) in patients with the...
Neoadjuvant Immunotherapy With Relatlimab and Nivolumab in Stage III Melanoma
The combination of immune checkpoint inhibitors relatlimab and nivolumab for patients with stage III melanoma given before surgery was safe and completely cleared all viable tumor in 57% of patients in a phase II study, according to findings published by Amaria et al in Nature. In addition to...
EXTEND Trial: Metastasis-Directed Radiation Therapy Plus Hormone Therapy May Improve Progression-Free Survival in Patients With Advanced Prostate Cancer
Researchers from The University of Texas MD Anderson Cancer Center demonstrated that adding metastasis-directed radiation therapy to intermittent hormone therapy improved progression-free survival in patients with oligometastatic prostate cancer. Findings from the multicenter EXTEND trial were...
FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma
On October 25, the U.S. Food and Drug Administration (FDA) granted accelerated approval to teclistamab-cqyv (Tecvayli), the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myeloma who have received at least four...
Richter Transformation Remains Challenging, but Better Treatments Are on the Horizon
Richter transformation, usually a diffuse large B-cell lymphoma developing in a person with CLL, remains a challenging entity, but novel regimens look promising, as described at the 2022 Pan Pacific Lymphoma Conference by Matthew S. Davids, MD, MMSc, Associate Professor of Medicine at Harvard...
Timely Surveillance With Chest Imaging May Benefit Patients With Metastatic Colorectal Cancer
Patients with colorectal cancer who have certain clinical characteristics may benefit from more frequent chest imaging to help identify and target cancer that has metastasized to the lungs, according to a new study presented at the 2022 Scientific Forum of the American College of Surgeons Clinical...
Researchers Find Possible Link Between Immune Cells’ Closest Neighbors and Survival Time in Patients With Pancreatic Cancer
Researchers have discovered that the organization of different types of immune cells within pancreatic tumors may be associated with how well patients with pancreatic cancer respond to treatment, as well as how long they survive. This information could eventually lead to new ways of treating...
Expert Point of View: Amy Tiersten, MD and Carlos L. Arteaga, MD
Amy Tiersten, MD, Professor of Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai, and Carlos L. Arteaga, MD, Director of the Simmons Comprehensive Cancer Center and Associate Dean of Oncology at The University of Texas Southwestern Medical Center, Dallas,...
PADA-1 Trial: With Early Identification of ESR1 Mutation, Switch to Fulvestrant in Metastatic Breast Cancer
Switching from an aromatase inhibitor to fulvestrant upon early identification of the ESR1 mutation in plasma—before disease progression—doubled progression-free survival in the phase III PADA-1 trial, presented at the 2021 San Antonio Breast Cancer Symposium.1 “PADA-1 is the first trial to...
Strides Are Being Made in the Treatment of Brain Metastases From Breast Cancer
New drugs for HER2-positive breast cancer are able to overcome some of the obstacles that have made brain metastases challenging to treat, according to Mark Pegram, MD, the Susy Yuan-Huey Hung Professor of Oncology at Stanford University School of Medicine in California, who described the promising ...
Switch to Fulvestrant/Palbociclib With Rising ESR1 Mutation Level in Blood During Aromatase Inhibitor/Palbociclib Therapy in Patients With Advanced Breast Cancer
As reported in The Lancet Oncology by François-Clément Bidard, MD, and colleagues, the French phase III PADA-1 trial has shown that switching to fulvestrant/palbociclib vs continuing first-line aromatase inhibitor (AI)/palbociclib therapy was associated with improved progression-free survival among ...
Managing Lymphomas in the Future: Some Bright Spots Are Emerging
Although standard therapies may provide long-lasting remissions for many patients with various subtypes of lymphoma, there is a critical need for new strategies for the sizable high-risk subset. At the 2022 Pan Pacific Lymphoma Conference, four experts in the field described future therapies for...
Mechanism Linking Air Pollution to Lung Cancer Identified
Although air pollution is associated with lung cancer, not much has been known about how one leads to the other. For the first time, researchers have identified a mechanism by which particulate matter in the air triggers non–small cell lung cancer (NSCLC) in people who have never smoked. Moreover,...
What Is the Best Induction Regimen for Newly Diagnosed PCNSL?
Primary central nervous system lymphoma (PCNSL) accounts for less than 1% of all non-Hodgkin lymphomas and between 3% and 4% of all brain tumors, with an age-adjusted incidence rate of four cases per million persons per year. Approximately 1,500 new cases are diagnosed each year in the United...
Stephen A. Strickland, Jr, MD, MSCI, Joins the Sarah Cannon Transplant & Cellular Therapy Network
Sarah Cannon, the Cancer Institute of HCA Healthcare, announced recently that Stephen A. Strickland, Jr, MD, MSCI, has been named the Director of Leukemia Research for the Transplant & Cellular Therapy Network. In this role, Dr. Strickland provides scientific leadership and oversees Sarah...
Expert Point of View: Hisashi Saji, MD
Abstract discussant Hisashi Saji, MD, Chair of Thoracic Surgery at St. Marianna University School of Medicine, Kawasaki, Japan, said that, based on two recently reported phase III studies, sublobar resection, including wedge resection and segmentectomy, must be considered as a standard of care for...
Chemotherapy for Children With Type II or III Pleuropulmonary Blastoma
In an analysis from the International PPB/DICER1 Registry reported in the Journal of Clinical Oncology, Schultz et al found that chemotherapy with IVADo (ifosfamide, vincristine, actinomycin-D, and doxorubicin) appeared to be associated with similar or improved outcomes vs historical controls among ...
Addition of PD-1 Inhibitor Serplulimab to Chemotherapy in the First-Line Treatment of Extensive-Stage SCLC
As reported in JAMA by Cheng et al, an interim analysis of the phase III ASTRUM-005 trial has shown that the addition of the PD-1 inhibitor serplulimab to chemotherapy improved overall survival in the first-line treatment of patients with extensive-stage small cell lung cancer (SCLC). Study ...
Study Focuses on Molecular Details of Precancerous Clonal Outgrowth in Blood Cells
A common, spontaneous mutation in blood stem cells, which has been linked to a higher risk of blood cancer and cardiovascular disease, may promote these diseases by altering the stem cells’ programming of gene activity and the mix of blood cells they produce, according to a study co-led by...
Researchers Identify Potential Biomarker to Distinguish Group 3 and Group 4 Medulloblastomas
It may soon be possible to identify group 4 medulloblastomas from more aggressive group 3 tumors. Research based on a little-explored part of RNA that creates proteins may lead to the development of better-targeted therapies, according to investigators at the Johns Hopkins Kimmel Cancer Center....
Managing the Risk of Thrombosis in Polycythemia Vera
This is Part 1 of Updates in Myeloproliferative Neoplasms, a three-part video roundtable series. Stay tuned for future installments in the coming months. In this video, Dr. Prithviraj Bose and Dr. Ruben Mesa discuss how best to manage the risk of thrombosis in patients with polycythemia vera....
Tissue vs ctDNA NGS for Detecting Actionable Alterations in Patients With Advanced Cancer
A large prospective analysis, published by Bayle et al in Annals of Oncology, evaluated differences between tissue and circulating tumor DNA (ctDNA) next-generation sequencing (NGS) with a large cancer gene panel. The investigators compared the impacts of both methods in terms of molecular tumor...
Lasker Foundation Announces 2022 Lasker Award Winners
On September 28, the Lasker Foundation announced the winners of the 2022 Albert Lasker Basic Medical Research Award, the 2022 Lasker~DeBakey Clinical Medical Research Award, and the 2022 Lasker~Bloomberg Public Service Award. Albert Lasker Basic Medical Research Award Richard O. Hynes, PhD, of the...
Constitutional BRCA1 Methylation and Risk of Triple-Negative Breast Cancer and Ovarian Cancer
In a case-control study within the U.S. Women’s Health Initiative (WHI) study population reported in JAMA Oncology, Lønning et al found that BRCA1 promoter methylation identified in white blood cells was associated with increased risks of incident triple-negative breast cancer and high-grade serous ...
Blood Pressure and Risk of Heart Failure in Patients With Cancer
In a Japanese study reported in the Journal of Clinical Oncology, Kaneko et al found that hypertension in patients with cancer not receiving blood pressure–lowering medication was associated with an increased risk of heart failure and other cardiovascular disease events. Study Details The...
A Physicist Father Inspired a Love of Science in Oncology Researcher Stanton L. Gerson, MD
In this installment of the Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Stanton (“Stan”) L. Gerson, MD, Dean and Senior Vice President for Medical Affairs, School of Medicine, and Acting Director of the Case Comprehensive Cancer Center and National Center for...
Changing the Algorithm for Relapsed or Refractory Large B-Cell Lymphomas
Despite a significant potential for cure, relapsed and refractory large B-cell lymphomas (LBCL) comprise the most common cause of lymphoma-related mortality. Sequential relapses reflect the limits of repeated exposure to chemotherapy, even when delivered at high doses. More than 30 years ago,...
Determining Prognosis in Aggressive Lymphomas: Integrating Liquid Biopsy Into Imaging Assessment
The incorporation of blood-based measurements—ie, “liquid biopsies”—into imaging assessment may refine the accuracy of prognosis in aggressive lymphomas, as described by David Kurtz, MD, PhD, Assistant Professor in the Division of Oncology, Stanford University Medical Center, in a talk at the 2022...
Axicabtagene Ciloleucel Improves Event-Free Survival vs Standard Care in Second-Line Treatment for Large B-Cell Lymphoma
As reported in The New England Journal of Medicine by Frederick L. Locke, MD, of the Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, Florida, and colleagues, the phase III ZUMA-7 trial in large B-cell lymphoma has shown improved event-free...
Patients With Multiple Myeloma May Face CAR T-Cell Shortages
From microchips to automobiles, people in the United States are experiencing shortages of all kinds of products, and oncology treatments are no exception. In particular, shortages related to chimeric antigen receptor (CAR) T-cell therapy have been reported, most acutely, for B-cell maturation...
Practice-Changing Studies, Important New Data, and More Clinical Oncology News From ESMO 2022, Paris
The European Society For Medical Oncology (ESMO) launched its annual congress, held September 9–13, 2022, just as this issue of The ASCO Post was going to press. Watch upcoming issues for comprehensive coverage of the live congress, following 2 years of virtual meetings and remote presentations due ...
HER2-Positive Colorectal Cancer
This is Part 3 of Updates in Colorectal Cancer, a four-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Cathy Eng, Arvind Dasari, and Smitha Krishnamurthi discuss the management of HER2-positive colorectal cancer. The patient is a...
Neoadjuvant Atezolizumab May Be Safe, Effective Option for Localized Non–Small Cell Lung Cancer
New data show that the immuno-oncology drug atezolizumab may be a safe and effective treatment for patients with stage IB to IIIB non–small cell lung cancer (NSCLC) prior to surgery, according to a study led by researchers with The Ohio State University Comprehensive Cancer Center–Arthur G. James...
Preclinical Study Finds New Synthetic Lethal Agent Could Be Potential Treatment for Pancreatic Cancer
Researchers at The Marvin and Concetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center have found that a new synthetic lethal agent could be an effective treatment for pancreatic cancers with DNA damage repair (DDR) defects. Igor Astsaturov, MD, PhD, a co-director of the Institute...
Research Explores Multicancer Early Detection Blood Testing
Physicians, care providers, and payers may be preparing for a major shift in early cancer detection that will affect almost every stage of cancer diagnosis and treatment. New data supporting the accuracy of multicancer early detection blood testing, presented by Deb Schrag, MD, FASCO, MPH, at the...
FDA Approves Eflapegrastim-xnst Injection for Chemotherapy-Induced Neutropenia
On September 9, the U.S. Food and Drug Administration (FDA) approved eflapegrastim-xnst injection (Rolvedon)—a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation—to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with...
Researchers Examine How Air Pollution May Drive Lung Cancer in Never-Smokers
A new mechanism has been identified through which very small pollutant particles in the air may trigger lung cancer in people who have never smoked, paving the way to new prevention approaches and the development of novel therapies, according to late-breaking data reported by Charles Swanton, MBBS, ...
